Premium
Malignant transformation of neurocutaneous melanosis ( NCM ) following immunosuppression
Author(s) -
Schaff Lauren R.,
Marghoob Ashfaq,
Rosenblum Marc K.,
Meyer Rina,
Khakoo Yasmin
Publication year - 2019
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.13804
Subject(s) - leptomeninges , medicine , malignant transformation , immunosuppression , melanoma , melanosis , melanocyte , hydrocephalus , pathology , parenchyma , dermatology , cancer research , immunology , surgery , central nervous system
Neurocutaneous melanosis ( NCM ) is the condition of abnormal melanocyte deposition in the leptomeninges and brain parenchyma. Associated with congenital melanocytic nevi, NCM can result in neurologic deficits, hydrocephalus, and rarely, malignant transformation of cells. We present the case of a 16‐year‐old boy with NCM who developed malignant leptomeningeal melanoma following immunosuppression with a TNF α inhibitor. To our knowledge, this is the first reported case of a patient with known NCM undergoing malignant transformation after anti‐ TNF therapy for inflammatory bowel disease.